Improvements in 2 patient-reported outcome measures were observed among patients with psoriasis treated with deucravacitinib vs placebo or apremilast.

No new safety concerns and consistent safety profiles were observed for long-term risankizumab use in patients with psoriasis and PsA.

Check the time stamp on this data. Updated AI-Generated Signals for Pearson Plc (PSO) available here: PSO.

PSO sent the proposal to the Oklahoma Corporation Commission earlier this week. Just so we're clear, the Commission must ...

If the deal goes through, PSO said the average residential customer using 1,100 kWh per month would see an increase of $7.24 ...

1 Day PSO 1.23% DJIA -0.25% S&P 500 -0.29% Energy 1.41% ...

Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high ...

PSO’s HSD and MS sales were down by 8 percent and 1 percent year-on-year, respectively, in FY24, while FO sales decreased by 76 percent year-on-year. The company’s overall market share ...

Try your luck during The Price is Right Live at Cross Insurance Arena in Portland on Sept. 25.

1 Day PSO 1.51% DJIA 0.72% S&P 500 0.54% Energy 0.60% ...